---
title: "extreme"
date: "2024-09-28"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[palliative_intent-of-hnscc]]

# extreme

EXTREME trial: Cetuximab plus platinum-based chemotherapy significantly prolonged the median overall survival from 7.4 months to 10.1 months, improved median progression-free survival time from 3.3 to 5.6 months, and increased the response rate from 20% to 36% in patients with untreated recurrent or metastatic squamous-cell carcinoma of the head and neck.

> 1.Vermorken JB. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. The New England Journal of Medicine. Published September 11, 2008. Accessed September 28, 2024. <https://www.nejm.org/doi/full/10.1056/NEJMoa0802656>
